11 / 28
Olaparib improves PFS and ORR in gBRCAm MBC
OLIMPIA
Olaparib
TPC (Cape, VNR, Eribulin)
gBRCAm MBC
<2 previous lines
Robson ME. NEJM 2017
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Progression Free Survival
Time from randomisation (months)
14
12
10
8 6 4 2 0
16 18 20 22 24 26 28
Olaparib 300 mg bd (N=205)
TPC (N=97)
Olaparib
TPC
n
205
97
Median PFS
7.0 m 4.2 m
HR =
0.58
(0.43, 0.80)
p=0.0009
Olaparib
TPC
n
167
66
ORR
59.9% 28.8%
Randomise 2:1
N=302
Stratification by
•
Prior chemo regimens MBC
•
Hormonal receptor status
•
Prior platinum therapy